Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
28 February 2020Website:
http://www.passagebio.comNext earnings report:
13 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 22:04:39 GMTDividend
Analysts recommendations
Institutional Ownership
PASG Latest News
PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Mr. Kassberg is currently Chief Business Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultrarare genetic diseases.
Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy to GEMMA Biotherapeutics, a new company co-founded by Dr. James M. Wilson
The heavy selling pressure might have exhausted for Passage Bio (PASG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Passage Bio (PASG) has been upgraded to a Zacks Rank #2 (Buy), indicating increasing confidence in the company's earnings potential. This could lead to a rise in the stock price in the short run.
Does Passage Bio, Inc. (PASG) have what it takes to be a top stock pick for momentum investors? Let's find out.
What type of business is Passage Bio?
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
What sector is Passage Bio in?
Passage Bio is in the Healthcare sector
What industry is Passage Bio in?
Passage Bio is in the Biotechnology industry
What country is Passage Bio from?
Passage Bio is headquartered in United States
When did Passage Bio go public?
Passage Bio initial public offering (IPO) was on 28 February 2020
What is Passage Bio website?
https://www.passagebio.com
Is Passage Bio in the S&P 500?
No, Passage Bio is not included in the S&P 500 index
Is Passage Bio in the NASDAQ 100?
No, Passage Bio is not included in the NASDAQ 100 index
Is Passage Bio in the Dow Jones?
No, Passage Bio is not included in the Dow Jones index
When was Passage Bio the previous earnings report?
No data
When does Passage Bio earnings report?
The next expected earnings date for Passage Bio is 13 November 2024